Inflammatory Pain- Pipeline Insight, 2025

This “Inflammatory Pain- Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Inflammatory Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Inflammatory Pain: Understanding

Inflammatory Pain: Overview

Inflammatory pain is a type of pain that arises due to the activation of the immune system in response to tissue injury, infection, or autoimmune processes. This form of pain is characterized by the presence of inflammation, which serves both to eliminate the initial cause of cell injury and to initiate repair processes. Common conditions associated with inflammatory pain include arthritis, tendonitis, and inflammatory bowel disease. The primary function of inflammation is protective, but it can also lead to chronic pain if the inflammatory response is prolonged or improperly regulated. The signs and symptoms of inflammatory pain include redness, heat, swelling, and loss of function in the affected area, accompanied by a throbbing, aching, or sharp pain. Patients often experience tenderness when the affected area is touched or moved. In chronic conditions, symptoms may persist and can include fatigue, stiffness, and decreased range of motion. The pain may worsen with activity and improve with rest, although in some cases, it may persist even at rest.

The causes of inflammatory pain are diverse and can include physical injury, infections (bacterial, viral, or fungal), and autoimmune disorders where the body’s immune system attacks its own tissues. Other factors like prolonged stress, poor diet, and certain genetic predispositions can also contribute to the development of inflammatory conditions. Common inflammatory mediators involved in this type of pain include cytokines, prostaglandins, and leukotrienes, which play a crucial role in sustaining the inflammatory response. Pathophysiologically, inflammatory pain involves the activation of nociceptors (pain receptors) by inflammatory mediators released from immune cells. This process increases the sensitivity of nociceptors, leading to heightened pain perception. Additionally, the inflammation can cause changes in the nervous system, such as central sensitization, where neurons in the spinal cord and brain become more responsive to pain signals. This sensitization can perpetuate pain even after the initial injury or infection has resolved.

Diagnosis of inflammatory pain typically involves a comprehensive medical history, physical examination, and diagnostic tests such as blood tests to identify markers of inflammation (e.g., elevated C-reactive protein, erythrocyte sedimentation rate), imaging studies (e.g., X-rays, MRI) to assess the extent of tissue damage, and sometimes biopsy of affected tissues. Treatment strategies focus on addressing both the pain and the underlying inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) are commonly used to reduce inflammation and manage pain. Additionally, physical therapy, lifestyle modifications (such as diet and exercise), and complementary therapies (such as acupuncture and massage) can help alleviate symptoms and improve quality of life for individuals with inflammatory pain.

'Inflammatory Pain- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inflammatory Pain pipeline landscape is provided which includes the disease overview and Inflammatory Pain treatment guidelines. The assessment part of the report embraces, in depth Inflammatory Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inflammatory Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Inflammatory Pain R&D. The therapies under development are focused on novel approaches to treat/improve Inflammatory Pain.

Inflammatory Pain Emerging Drugs Chapters

This segment of the Inflammatory Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Inflammatory Pain Emerging Drugs

HT-6184: Halia Therapeutics, Inc.

HT-6184 represents an innovative approach as it is the first drug candidate to target the protein NEK7 through an allosteric mechanism. NEK7 is an essential component of the NLRP3 inflammasome and is critical for its assembly and the maintenance of NLRP3 activity. Preclinical models also showed that in addition to disrupting the formation of the NLRP3 inflammasome, HT-6184 promotes the disassembly of the inflammasome once activated (Halia unpublished data). HT-6184 is formulated for oral, intranasal, and ophthalmic administration, for ease of patient use. Due to its high potency, HT-6184 effective doses are predicted to be very low, greatly reducing the potential for drug-induced liver toxicity. Unlike currently approved IL-1b-targeted therapies, HT-6184 targets upstream of the NLRP3 pathway, and not its downstream effector cytokines IL-1b and IL-18. Therefore, the expectation is that HT-6184 will selectively target dysfunctional chronic inflammation in disease tissue, leaving intact the homeostatic acute inflammatory responses needed for daily protective immunity and thereby diminishing opportunistic infection risk. Currently, the drug is in Phase II stage of its development for the treatment of inflammatory pain.

SUPERA 1R: MyMD Pharmaceuticals

Supera-CBD is a novel synthetic molecule preclinical cannabidiol derivative that targets CB2 receptors. Supera-CBD is non-toxic and approximately 7-8X more effective than plant-derived CBD in reducing MAO-A and MAO-B, which play a role in substance addiction, in a dose-dependent manner. Supera-CBD is being developed to address anxiety, chronic pain, and seizures and is expected to begin human trials as a therapy for epilepsy, followed by chronic pain. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based CBD. Opioid receptors are G protein-coupled receptors, widely expressed in the brain, spinal cord, peripheral neurons, and digestive tract. In studies with scientific collaborators, Supera-CBD has demonstrated antidepressant and anti-anxiety effects with much higher potency and efficacy than plant-derived CBD. CBD has broad therapeutic properties across a range of neuropsychiatric disorders, but without the psychoactive effects of THC. Currently, the drug is in preclinical stage of its development for the treatment of inflammatory pain.

Inflammatory Pain: Therapeutic Assessment

This segment of the report provides insights about the different Inflammatory Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Inflammatory Pain

• There are approx. 5+ key companies which are developing the therapies for Inflammatory Pain. The companies which have their Inflammatory Pain drug candidates in the most advanced stage, i.e. phase II include, Halia Therapeutics, Inc.

Phases

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Inflammatory Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Inflammatory Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inflammatory Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inflammatory Pain drugs.

Inflammatory Pain Report Insights

• Inflammatory Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Inflammatory Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Inflammatory Pain drugs?
• How many Inflammatory Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inflammatory Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Inflammatory Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Inflammatory Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Halia Therapeutics, Inc.

MyMD Pharmaceuticals

• Centrexion Therapeutics Corp.

AfaSci

• Gesynta Pharma AB

Key Products

• HT-6184
• SUPERA 1R
• CNTX-6970
• AFA-103
• GS-073

This product will be delivered within 2 business days.